NCT03492424 is a clinical trial of cryotherapy in Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT03492424?

NCT03492424 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT03492424?

Interventions in NCT03492424: cryotherapy.

What condition does NCT03492424 study?

NCT03492424 studies Prostate Cancer.

Is NCT03492424 still recruiting?

NCT03492424 is currently recruiting now. Last updated 23 December 2025.

Last reviewed 2025-12-23 · How we verify

NCT03492424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ablative Therapy in the Management of Prostate Cancer

Recruiting now Last updated 23 December 2025

What this trial tests

trial testing cryotherapy in Prostate Cancer in 200 participants. Currently enrolling.

Timeline

2 January 2018

Primary endpoint
2 March 2032

2 September 2039

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	2 January 2018
Primary completion	2 March 2032
Estimated completion	2 September 2039
Sites	1 location across United States

Drugs / interventions tested

cryotherapy (CRYOTHERAPY) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Weill Medical College of Cornell University

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications.
Bachu VS, Kedda J, Suk I, Green JJ, et al · · 2021 · cited 166× · PMID 34374945 · DOI 10.1007/s10439-021-02833-9
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08
Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.
Wahnou H, Youlyouz-Marfak I, Liagre B, Sol V, et al · · 2023 · cited 20× · PMID 37376215 · DOI 10.3390/pharmaceutics15061767
Focal therapy, time to join the multi-disciplinary team discussion?
Reddy D, Bedi N, Dudderidge T. · · 2020 · cited 2× · PMID 32676440 · DOI 10.21037/tau.2019.09.30

Verify or expand the search:

Other trials of cryotherapy

Trials testing the same drug.

NCT06106386 — The Effect of Different Intraradicular Cryotherapy on Post-operative Pain and the Level of Substance P · NA · completed
NCT06020222 — The Effect of Cryotherapy on Breast Cancer Patients · NA · unknown
NCT06005389 — Serum Galectin-3 as a Marker of Human Papillomavirus Infection · completed
NCT04571307 — Cryotherapy in Breast B3 Lesions · NA · unknown
NCT04760873 — Cryotherapy for GAVE · NA · withdrawn

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03492424 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 23 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing